A new tool for detection of type I interferon activation in systemic lupus erythematosus

The IFN-I pathway is activated in systemic lupus erythematosus (SLE) and appears to be important in the pathogenesis of the disease. As a result, several clinical trials of anti-IFN monoclonal antibodies, which hold promise to control the disease, have been launched. Additionally, activation of IFN-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirou, Kyriakos A, Kalliolias, George D
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945060/
https://www.ncbi.nlm.nih.gov/pubmed/20815919
http://dx.doi.org/10.1186/ar3114
_version_ 1782187171796484096
author Kirou, Kyriakos A
Kalliolias, George D
author_facet Kirou, Kyriakos A
Kalliolias, George D
author_sort Kirou, Kyriakos A
collection PubMed
description The IFN-I pathway is activated in systemic lupus erythematosus (SLE) and appears to be important in the pathogenesis of the disease. As a result, several clinical trials of anti-IFN monoclonal antibodies, which hold promise to control the disease, have been launched. Additionally, activation of IFN-I might be important in the prognosis and activity assessment of the disease. Therefore, new biomarkers that reflect activity of the IFN-I pathway and are simple to measure, such as the monocyte CD64 receptor, are expected to have a great impact on the management of SLE, if properly validated.
format Text
id pubmed-2945060
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29450602011-02-26 A new tool for detection of type I interferon activation in systemic lupus erythematosus Kirou, Kyriakos A Kalliolias, George D Arthritis Res Ther Editorial The IFN-I pathway is activated in systemic lupus erythematosus (SLE) and appears to be important in the pathogenesis of the disease. As a result, several clinical trials of anti-IFN monoclonal antibodies, which hold promise to control the disease, have been launched. Additionally, activation of IFN-I might be important in the prognosis and activity assessment of the disease. Therefore, new biomarkers that reflect activity of the IFN-I pathway and are simple to measure, such as the monocyte CD64 receptor, are expected to have a great impact on the management of SLE, if properly validated. BioMed Central 2010 2010-08-26 /pmc/articles/PMC2945060/ /pubmed/20815919 http://dx.doi.org/10.1186/ar3114 Text en Copyright ©2010 BioMed Central Ltd
spellingShingle Editorial
Kirou, Kyriakos A
Kalliolias, George D
A new tool for detection of type I interferon activation in systemic lupus erythematosus
title A new tool for detection of type I interferon activation in systemic lupus erythematosus
title_full A new tool for detection of type I interferon activation in systemic lupus erythematosus
title_fullStr A new tool for detection of type I interferon activation in systemic lupus erythematosus
title_full_unstemmed A new tool for detection of type I interferon activation in systemic lupus erythematosus
title_short A new tool for detection of type I interferon activation in systemic lupus erythematosus
title_sort new tool for detection of type i interferon activation in systemic lupus erythematosus
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945060/
https://www.ncbi.nlm.nih.gov/pubmed/20815919
http://dx.doi.org/10.1186/ar3114
work_keys_str_mv AT kiroukyriakosa anewtoolfordetectionoftypeiinterferonactivationinsystemiclupuserythematosus
AT kallioliasgeorged anewtoolfordetectionoftypeiinterferonactivationinsystemiclupuserythematosus
AT kiroukyriakosa newtoolfordetectionoftypeiinterferonactivationinsystemiclupuserythematosus
AT kallioliasgeorged newtoolfordetectionoftypeiinterferonactivationinsystemiclupuserythematosus

Ejemplares similares